Tarceva for Pancreatic cancer (with gemcitabine)
Quick answer: Tarceva is used for Pancreatic cancer (with gemcitabine) as part of a egfr tyrosine kinase inhibitor treatment regimen. Reversibly inhibits the tyrosine kinase activity of the epidermal growth factor receptor (EGFR), blocking downstream tumor signaling The specific dosing for Pancreatic cancer (with gemcitabine) is determined by your prescriber based on individual factors.
Why is Tarceva used for Pancreatic cancer (with gemcitabine)?
Tarceva belongs to the EGFR tyrosine kinase inhibitor class. Reversibly inhibits the tyrosine kinase activity of the epidermal growth factor receptor (EGFR), blocking downstream tumor signaling This action makes it useful for treating or managing Pancreatic cancer (with gemcitabine) in patients for whom this approach is clinically appropriate.
It is one of several treatment options. Whether Tarceva is the right choice for a specific patient depends on the type and severity of Pancreatic cancer (with gemcitabine), response to previous treatments, individual risk factors, and clinical guidelines.
Typical dosing for Pancreatic cancer (with gemcitabine)
Common adult dosing range: 100-150 mg once daily. The actual dose for Pancreatic cancer (with gemcitabine) depends on:
- Severity of the condition
- Patient's age, weight, and organ function
- Other medications being taken
- Treatment response and tolerability
For complete dosing details, see the Tarceva medicine page.
What to expect
Tarceva treatment for Pancreatic cancer (with gemcitabine) typically involves:
- Onset of effect: varies by indication and dose — some effects are immediate, others take days to weeks
- Treatment duration: some courses are short-term, others are long-term or lifelong depending on Pancreatic cancer (with gemcitabine)
- Monitoring: follow-up visits to assess response and adjust dosing
- Side-effect awareness: learning what to expect and what warrants medical attention
Alternatives to consider
If Tarceva is not appropriate or not tolerated, alternatives within the same class or different therapeutic classes may be considered. See all EGFR tyrosine kinase inhibitor for related options.
When to talk to your doctor
Discuss with your prescriber if you experience:
- Inadequate symptom control on Tarceva
- Side effects affecting daily life
- New medications or supplements that may interact
- Pregnancy planning or pregnancy
- Major changes in health status
Related information
Tarceva full prescribing information · All EGFR tyrosine kinase inhibitor alternatives
Frequently asked questions
How effective is Tarceva for Pancreatic cancer (with gemcitabine)?
Effectiveness varies by individual response, dose, and severity. Tarceva is one of several treatment options for Pancreatic cancer (with gemcitabine), supported by clinical evidence within the egfr tyrosine kinase inhibitor class. Discuss expected response with your prescriber.
How long do I need to take Tarceva for Pancreatic cancer (with gemcitabine)?
Treatment duration depends on the nature of Pancreatic cancer (with gemcitabine) — some treatments are short-term, others long-term or lifelong. Never stop on your own; discontinuation requires clinical guidance to avoid relapse or rebound effects.
What are the main side effects of Tarceva when used for Pancreatic cancer (with gemcitabine)?
Common and serious side effects are class-related and substance-specific. See the full medicine page for the complete profile. Report any unexpected effects to your prescriber.
Are there alternatives to Tarceva for Pancreatic cancer (with gemcitabine)?
Yes. Multiple medicines and non-drug options exist for Pancreatic cancer (with gemcitabine). Alternatives within the egfr tyrosine kinase inhibitor class share mechanisms; other classes may offer different approaches. Discuss with your clinician.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.